The clinical performance is complex and often involves multi-system fatigue. Early identification and standardized diagnostics are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of IBD associated with colorectal cancer risk requires individualized development, typically including multidimensional management of drug therapy, rehabilitation, regular follow-up, and so on. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of the risk of IBD-associated colorectal cancer. The platform serves a team of domestically and internationally authoritative experts in the field of infectious respiratory digestive endocrine in China.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.